Keytruda is Merck's brand name for pembrolizumab, a PD-1 checkpoint inhibitor monoclonal antibody that helps the immune system attack cancer cells. The FDA has approved Keytruda for more than 40 indications since 2014, including non-small cell lung cancer, melanoma, head and neck cancer, classical Hodgkin lymphoma, urothelial carcinoma, cervical cancer, hepatocellular carcinoma, renal cell carcinoma, endometrial cancer, triple-negative breast cancer, and solid tumors with microsatellite instability-high (MSI-H) or high tumor mutational burden status. Merck supplies standard Keytruda as a 100 mg per 4 mL single-dose vial given by intravenous infusion over about 30 minutes, typically 200 mg every 3 weeks or 400 mg every 6 weeks. In September 2025, the FDA also approved Keytruda Qlex, a subcutaneous co-formulation with berahyaluronidase alfa that can be injected in about 1 minute at a fixed 395 mg or 790 mg dose. Because both versions require administration by a healthcare professional, Keytruda is billed under Medicare Part B and commercial medical benefits rather than through a retail pharmacy or Medicare Part D.
Merck's 2026 list price for Keytruda runs $12,272 for a 200 mg infusion and $24,544 for a 400 mg infusion, based on the company's published wholesale acquisition cost. Actual charges vary widely by where treatment happens. Serif Health's price-transparency research puts commercial negotiated rates for a 200 mg dose anywhere from just under $12,000 to more than $30,000, a five-to-tenfold spread across providers in the same market. Physician offices and freestanding infusion centers typically charge less than hospital outpatient departments because they carry lower facility overhead and do not layer on a separate facility fee. Patients paying cash without insurance should expect roughly $10,000 to $14,000 per infusion, and a full year of treatment, often 17 or more infusions on the every-3-week schedule, can exceed $150,000 to $200,000 before any discount, copay assistance, or Patient Assistance Program is applied.
Under the Inflation Reduction Act of 2022, Medicare selects a new batch of high-spend drugs each year for price negotiation, with negotiated Maximum Fair Prices phased in over subsequent years. Keytruda was widely expected to be selected for the third negotiation round covering prices effective 2029, given its position as one of Medicare's highest-spending Part B drugs. A 2025 federal reconciliation law broadened the orphan-drug exclusion and specifically delayed Keytruda's (and Bristol Myers Squibb's Opdivo) negotiation eligibility, pushing the earliest possible selection to 2027 for a Maximum Fair Price effective around 2029, with further delay possible. Patients should not expect an IRA-negotiated price for Keytruda before 2029 at the earliest, so the manufacturer coupon, Patient Assistance Program, and standard Part B coinsurance rules described below remain the primary cost-management tools through 2026 and beyond.
What Keytruda Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same keytruda can cost many times more at a hospital than at your local pharmacy:
2026 Keytruda Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare Part B ASP rate (2026) | $11,442 ASP value; Medicare pays providers ~$12,129 (ASP + 6%); patient owes ~$2,290 - $2,430 (20% coinsurance) | Applies after the $283 2026 Part B deductible; Medigap or Medicare Advantage OOP maximums can eliminate the coinsurance |
| Cash/list price (no insurance) | $10,000 - $14,000/infusion | No retail pharmacy or GoodRx coupon applies; price varies by site of care |
| Commercial insurance (after prior authorization) | $0 - $3,000+/infusion until annual out-of-pocket max is met | Prior authorization with biomarker documentation (PD-L1, MSI-H, TMB) is standard; some plans place Keytruda on a specialty formulary tier under the medical benefit rather than a pharmacy formulary tier |
| Merck Access Program copay card | $0 - $25/infusion (commercial insurance only) | Ineligible if you have Medicare, Medicaid, TRICARE, VA, or no insurance |
| Medicaid | $0 - $4/infusion, with PA | Most states waive or minimize cost-sharing for chemotherapy and oncology infusions |
Costs reflect 2026 CMS ASP files, Merck's published list price, and Serif Health price-transparency research. Your actual bill depends on your specific plan design, site of care, and whether prior authorization was approved before the infusion.
Source: CMS Medicare Part B ASP Pricing Files (2026), Merck published list price, Serif Health price-transparency analysis
Why Hospitals Charge So Much
Hospital outpatient departments charge more for Keytruda than physician offices or freestanding infusion centers because they add a separate facility fee on top of the drug charge, covering nursing time, monitoring, and campus overhead. Serif Health's analysis of price-transparency files found commercial negotiated rates for a 200 mg Keytruda dose ranging from under $12,000 at the lowest-cost sites to more than $30,000 at the highest-cost hospital outpatient departments, a spread of five to ten times for the identical drug and dose. Medicare pays a uniform national rate (ASP plus 6%) regardless of site, but commercial insurers negotiate separately with each hospital system, and those negotiated rates are rarely disclosed to patients before treatment begins.
A single standard Keytruda vial holds 100 mg in 4 mL, so a 200 mg dose requires two vials. Hospitals bill HCPCS code J9271 in 1 mg units, meaning a 200 mg dose should appear on the claim as 200 units, not as a single line item or a flat unit count. Comparing your itemized bill's billed units against your prescribed milligram dose is one of the fastest ways to catch an overcharge. Wasted drug from a partially used vial is billable separately with the JW modifier, but only the amount actually discarded, not the full unused vial, should ever appear as an extra charge. A bill showing more units than your recorded dose, or a JW modifier charge larger than the realistic leftover vial amount, is worth disputing with the billing department before payment.
HCPCS J-Codes: What Appears on Your Bill
Keytruda is billed under two HCPCS Level II codes depending on formulation. Standard intravenous Keytruda uses J9271, and the newer subcutaneous Keytruda Qlex uses J9277 as of April 2026. Both codes represent 1 mg of pembrolizumab, so billed units should equal your prescribed milligram dose.
HCPCS J-codes for Keytruda| Code | Description | What to look for |
|---|
| J9271 | Injection, pembrolizumab, 1 mg (intravenous) | Confirm billed units equal your prescribed dose (200 units for a 200 mg dose, 400 units for a 400 mg dose); a flat unit count of 1 or a vial count instead of milligrams is a common upcoding error. |
| J9277 | Injection, pembrolizumab and berahyaluronidase alfa-pmph, 1 mg (subcutaneous, Keytruda Qlex) | Keytruda Qlex is dosed as a fixed 395 mg or 790 mg, not by body weight; confirm the units billed match one of those two fixed doses. |
HCPCS Level II J-codes are public-domain identifiers maintained by CMS for Medicare Part B drug billing.
Source: CMS HCPCS Level II code set, 2026
Patient Assistance Programs
Merck runs two distinct programs for Keytruda, and which one applies depends entirely on your insurance status. Commercially insured patients use a copay card through the Merck Access Program; uninsured and underinsured patients apply to the separate Merck Patient Assistance Program, which can supply Keytruda free of charge. An independent charity, the Patient Advocate Foundation, can also help cancer patients, including those on Medicare, with copay costs.
Patient assistance programs for Keytruda| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Merck Access Program Copay Card | As low as $0 - $25 per infusion for commercially-insured patients; Merck-reported data show about 80% of enrolled commercial patients paid between $0.01 and $375 per infusion | merckaccessprogram-keytruda.com |
| Merck Patient Assistance Program (Merck Helps) | Free Keytruda for uninsured or underinsured patients with household income up to approximately 500% of the federal poverty level ($79,800 for an individual in 2026) | merckhelps.com/KEYTRUDA |
| Patient Advocate Foundation Co-Pay Relief Program | Grants to cover cancer treatment copays and coinsurance for eligible patients, including those on Medicare, based on income and diagnosis fund availability | patientadvocate.org/copay-relief |
Federal anti-kickback law (42 U.S.C. Section 1320a-7b) bars manufacturer copay cards, including the Merck Access Program card, from being used by anyone on Medicare, Medicaid, TRICARE, or VA benefits. If you have government insurance, apply to the Merck Patient Assistance Program or an independent charity such as the Patient Advocate Foundation instead.
Source: Merck Access Program, Merck Patient Assistance Program (Merck Helps), Patient Advocate Foundation
Common Keytruda Billing Errors
Patients who receive a Keytruda bill higher than $3,000 with commercial insurance, or above $2,700 in Part B coinsurance for a single infusion, should check for these issues before paying:
- J9271 or J9277 units billed incorrectly, for example as 1 unit or as a vial count, instead of the actual milligram dose, inflating the drug charge.
- Wastage billed under the JW modifier for more milligrams than were actually discarded from the partially used vial.
- A hospital facility fee added to the drug charge without being itemized as a separate line so patients cannot verify it independently.
- Prior authorization that lapsed between infusion cycles, causing a mid-treatment denial even though the initial infusion was approved.
- The hospital's full chargemaster (list) rate applied to an insured patient's claim instead of the negotiated in-network rate.
- Part B coinsurance charged after a Medigap policy or Medicare Advantage annual out-of-pocket maximum should have already covered the balance.
Frequently Asked Questions
Is there a generic or biosimilar for Keytruda?
No generic or FDA-approved biosimilar for Keytruda (pembrolizumab) exists as of 2026. Keytruda is a biologic monoclonal antibody, so it cannot have a small-molecule generic; competition can only come through the biosimilar pathway under the Biologics Price Competition and Innovation Act. Merck's core intravenous-formulation patent for pembrolizumab is expected to expire around 2028. Several manufacturers, including Samsung Bioepis and companies in South Korea, India, and China, have started biosimilar development programs ahead of that date, but no pembrolizumab biosimilar is likely to reach US pharmacies before 2028 or 2029.
How do I apply for the Merck Patient Assistance Program for Keytruda?
Call the Merck Patient Assistance Program at 1-800-727-5400 or visit merckhelps.com/KEYTRUDA to start an application. Your oncologist's office typically completes and submits the enrollment form on your behalf, along with a prescription and proof of household income such as a recent tax return or pay stubs. The program primarily serves uninsured patients, though those with financial and medical hardship despite having partial coverage can request an exception. Approved patients receive Keytruda shipped directly to their treating provider at no cost, with eligibility reviewed periodically as treatment continues.
Can I use the Keytruda copay card with Medicare?
No. Federal anti-kickback law bars manufacturer copay cards, including the Merck Access Program card for Keytruda, from being used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits. The copay card is reserved for commercially insured patients and can lower out-of-pocket cost to as little as $0 to $25 per infusion. Medicare beneficiaries who need help affording their 20% Part B coinsurance should instead apply to the Merck Patient Assistance Program, an independent charity such as the Patient Advocate Foundation Co-Pay Relief Program, or ask about a Medicare Savings Program through their state Medicaid agency.
What if my insurance denies coverage for Keytruda?
Request the written denial notice, which must state the specific reason, then have your oncologist file a formal appeal within the plan's deadline, typically 60 days. Most Keytruda denials involve missing biomarker documentation, such as PD-L1 expression, microsatellite instability, or tumor mutational burden results tied to your specific cancer type and FDA-approved indication. Your oncologist can request a peer-to-peer review with the plan's medical director and, if denied again, escalate to an external review through your state's Department of Insurance. If appeals fail, the Merck Patient Assistance Program and Patient Advocate Foundation can help cover cost while you pursue coverage.
Does the IRA negotiated price apply to Keytruda in 2026?
No. Keytruda was not among the first 10 drugs negotiated under the Inflation Reduction Act (effective 2026) and was not selected in the second round (effective 2027). A 2025 reconciliation law broadened the orphan-drug exclusion and specifically delayed Keytruda's negotiation eligibility, pushing the earliest possible selection to 2027 for a Maximum Fair Price effective around 2029. Until then, Keytruda's price is set by Merck and negotiated separately between Merck and each insurer, with Medicare Part B paying providers based on the quarterly Average Sales Price.
What does Keytruda cost without insurance at the infusion center?
Cash price for Keytruda in 2026 runs about $10,000 to $14,000 per 200 mg infusion, close to Merck's published list price of $12,272. Because Keytruda must be administered by a healthcare professional, it is not available through a retail pharmacy or GoodRx coupon the way a pill or self-injectable would be. Where you receive treatment matters: freestanding infusion centers and physician offices typically charge less than hospital outpatient departments for the identical dose. Uninsured patients earning up to about 500% of the federal poverty level should apply to the Merck Patient Assistance Program before paying cash.
Do I qualify for the Merck Patient Assistance Program?
Eligibility depends on insurance status and household income. Merck's published thresholds are $79,800 or less for an individual, $108,200 or less for a couple, and $165,000 or less for a family of four in 2026, all approximately 500% of the federal poverty level. Applicants generally need to be uninsured or facing documented financial and medical hardship despite having some coverage, a valid Keytruda prescription from a US-licensed oncologist, and proof of US residency. Larger households qualify at proportionally higher income thresholds; see the household-size table above for exact figures.
What is the difference between Keytruda and Keytruda Qlex?
Keytruda is the original intravenous formulation of pembrolizumab, infused over about 30 minutes every 3 or 6 weeks at a weight-based dose of 200 mg or 400 mg. Keytruda Qlex, FDA-approved in September 2025, is a subcutaneous co-formulation with berahyaluronidase alfa that can be injected in about 1 minute at a fixed dose of 395 mg or 790 mg, without weighing the patient. Both share the same active ingredient and similar indications, but they bill under different HCPCS codes (J9271 for intravenous Keytruda, J9277 for Keytruda Qlex), and coverage or copay assistance terms can differ, so confirm which formulation your provider ordered before comparing costs.
